Paraoxonase 1 status as a risk factor for disease or exposure

Advances in Experimental Medicine and Biology

Volumn 660, Issue , 2010, Pages 29-35

  Richter, Rebecca J ^a   Jarvik, Gail P ^a   Furlong, Clement E ^a  

^a NONE

Author keywords

Carotid artery disease; Chlorpyrifos; Chlorpyrifos oxon; Diazinon; Diazoxon; OP exposure; Paraoxonase; PON1 status; Quorum sensing factor

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; DIAZOXON; N (3 OXODODECANOYL)HOMOSERINE LACTONE; ORGANOPHOSPHORUS COMPOUND; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL PROTOCOL; DROSOPHILA; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME SPECIFICITY; ENZYME SUBSTRATE COMPLEX; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; INFECTION RESISTANCE; METABOLITE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROCESS DEVELOPMENT; PROTEIN EXPRESSION; PROTEIN HYDROLYSIS; PSEUDOMONAS INFECTION; QUORUM SENSING; RISK ASSESSMENT; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

ANIMALS; ARYLDIALKYLPHOSPHATASE; BIOLOGICAL MARKERS; CAROTID ARTERY DISEASES; CHLORPYRIFOS; DROSOPHILA MELANOGASTER; HUMANS; HYDROLYSIS; INSECTICIDES; LACTONES; ORGANOPHOSPHORUS COMPOUNDS; OXIDATIVE STRESS; PARAOXON; POLYMORPHISM, SINGLE NUCLEOTIDE; PSEUDOMONAS; QUORUM SENSING; RISK; RISK FACTORS;

PSEUDOMONAS;

EID: 79956373494     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-60761-350-3_4     Document Type: Article

References (27)

1. Brophy VH, Jarvik GP, Furlong CE (2002) PON1 Polymorphisms. In: Costa LG, Furlong CE (eds. ). Paraoxonase (PON1) in Health and Disease: Basic and Clinical Aspects. Boston: Kluwer Academic Press. 53-77
2. Costa LG, Vitalone A, Cole TB and Furlong CE (2005) Modulation of paraoxonase (PON1) activity. Biochem Pharmacol 69:541-550
3. Chun CK, Ozer EA, Welsh MJ, Zabner J, Greenberg EP (2004) Inactivation of a Pseudomonas aeruginosa quorum sensing signal by human airway epithelia. Proc Natl Acad Sci USA 101:3587-3590 (Pubitemid 38338239)
4. Cole TB, Walter BJ, Shih DM, Tward AD, Lusis AJ, Timchalk C, Richter RJ, Costa LG, Furlong CE (2005) Toxicity of chlorpyrifos and chlorpyrifos oxon in a transgenic mouse model of the human paraoxonase (PON1) Q192R polymorphism. Pharmacogenet Genomics 15:589-598 (Pubitemid 41044245)
5. Costa LG, McDonald BE, Murphy SD, Omenn GS, Richter RJ, Motulsky AG, Furlong CE (1990) Serum paraoxonase and its influence on paraoxon and chlorpyrifos-oxon toxicity in rats. Toxicol Appl Pharmacol 103:66-76 (Pubitemid 20115985)
6. Davies H, Richter RJ, Keifer M, Broomfield C, Sowalla J, Furlong CE (1996) The human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nature Genet 14: 334-336
7. Deakin S, Leviev I, Brulhart-Meynet M-C, James RW (2003) Paraoxonase-1 promoter haplotypes and serum paraoxonase: a predominant role for polymorphic position ?107, implicating the Sp1 transcription factor. Biochem J 372:643-649 (Pubitemid 36723911)
8. Deakin SP, James RW(2004) Genetic and environmental factors modulating serum concentrations and activities of the antioxidant enzyme paraoxonase-1. Clin Sci (Lond. ) 107:435-447 (Pubitemid 39506735)
9. Eckerson HW, Wyte CM, La Du BN (1983) The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet 35:1126-1138 (Pubitemid 14201166)
10. Furlong CE, Richter RJ, Li W-F, Brophy VH, Carlson C, Meider M, Nickerson D, Costa LG, Ranchalis J, Lusis AJ, Shih DM, Tward A, Jarvik GP (2008) The functional consequences of polymorphisms in the human PON1 gene. In: Mackness B, Mackness M, Aviram M, Paragh G (eds). The Paraoxonases: Their Role in Disease, Development and Xenobiotic Metabolism. Dordrecht, The Netherlands: Springer. 267-281
11. Furlong C, Holland N, Richter R, Bradman A, Ho A, Eskenazi B (2006) PON1 status of farmworker mothers and children as a predictor of organophosphate sensitivity. Pharmacogenet Genomics 16:183-190
12. James RW. (2006) A long and winding road: defining the biological role and clinical importance of paraoxonases. Clin Chem Lab Med 44:1052-1059 (Pubitemid 44370921)
13. Jarvik GP, Rozek LS, Brophy VH, Hatsukami TS, Richter RJ, Schellenberg GD, Furlong CE (2000) Paraoxonase phenotype is a better predictor of vascular disease than PON1192 or PON155 genotype. Atheroscler Thromb Vasc Biol 20:2442-2447
14. Jarvik GP, Jampsa R, Richter RJ, Carlson C, Rieder M, Nickerson D, Furlong CE (2003) Novel paraoxonase (PON1) nonsense and missense mutations predicted by functional genomic assay of PON1 status. Pharmacogenetics 13:291-295 (Pubitemid 36583997)
15. La Du BN (2003) Future studies of low-activity PON1 phenotype subjects may reveal how PON1 protects against cardiovascular disease, Arterioscler Thromb Vasc Biol 23:1317-1318 (Pubitemid 36994516)
16. Lawlor DA, Day IN, Gaunt TR, Hinks LJ, Briggs PJ, KiesslingM, Timpson N, Smith GD, Ebrahim S (2004) The association of the PON1 Q192R polymorphism with coronary heart disease: findings from the British Women's Heart and Health cohort study and a meta-analysis. BMC Genet 5:17
17. Li W-F, Costa LG, Furlong CE (1993) Serum paraoxonase status: a major factor in determining resistance to organophosphates. J Toxicol Environ Health 40:337-346 (Pubitemid 23344358)
18. Li W-F, Furlong CE, Costa LG (1995) Paraoxonase protects against chlorpyrifos toxicity in mice. Toxicol Lett 76:219-226
19. Li W-F, Costa LG, Richter RJ, Hagen T, Shih DM, Tward A, Lusis AJ, Furlong CE (2000) Catalytic efficiency determines the in vivo efficacy of PON1 for detoxifying organophosphates. Pharmacogenetics 10:767-780
20. Mackness B, Davies GK, Turkie W, Lee E, Roberts DH, Hill E, Roberts C, Durrington PN, Mackness MI (2001) Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype? Arterioscler Thromb Vasc Biol 21:1451-1457 (Pubitemid 34219807)
21. Ozer EA, Pezzulo A, Shih DM, Chun C, Furlong C, Lusis AJ, Greenberg EP, Zabner J (2005) Human and murine Paraoxonase 1 are host modulators of P. aeruginosa quorum-sensing. FEMS Microbiol Lett 253:29-37 (Pubitemid 41605391)
22. Richter RJ, Furlong CE (1999) Determination of paraoxonase (PON1) status requires more than genotyping. Pharmacogenetics 9:745-753 (Pubitemid 30011938)
23. Richter RJ, Jarvik GP, Furlong CE (2008) Determination of paraoxonase 1 status without the use of toxic organophosphate substrates. Circ Cardiovasc Genet 1:147-152 DOI: 10.1161/CIRCGENETICS.108.811638
24. Richter RJ, Jarvik GP, Furlong CE (2009) Paraoxonase 1 (PON1) status and substrate hydrolysis. Toxicol Appl Pharmacol 235:1-9
25. Shih DM, Gu L, Xia Y-R, Navab M, Li W-F, Hama S, Castellani LW, Furlong CE, Costa, LG, Fogelman AM, Lusis AJ (1998) Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 394:284-287 (Pubitemid 28335041)
26. Stoltz DA, Ozer EA, Taft PJ, Barry M, Liu L, Kiss PJ, Moninger TO, Parsek MR, Zabner J (2008) Drosophila are protected from Pseudomonas aeruginosa lethality by transgenic expression of paraoxonase-1. J Clin Invest 118:3123-3131 doi:10.1172/JCI35147
27. Wheeler JG, Keavney BD, Watkins H, Collins R, Danesh J (2004) Four paraoxonase gene polymorphisms in 11212 cases of coronary heart disease and 12786 controls: meta-analysis of 43 studies. Lancet 363:689-695. (Pubitemid 38296555)